

10/586814

IAP11 Rec'd PCT/PTO 24 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Peter HEROLD et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_0979A
Filed July 24, 2006 :
DIAMINO ALCOHOLS AND THEIR : THE COMMISSIONER IS AUTHORIZED
USE AS RENIN INHIBITOR : TO CHARGE ANY DEFICIENCY IN THE
[Corresponding to PCT/EP2005/050272 : FEE FOR THIS PAPER TO DEPOSIT
Filed January 21, 2005] ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified


- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report (International Search Report) citing one or more of the references is enclosed.

Respectfully submitted,

Peter HEROLD et al.

By:



Michael R. Davis

Registration No. 25,134

Attorney for Applicants

MRD/pth
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 24, 2006

10/586814
 IAP11 Rec'd PCT/PTO 24 JUL 2006

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
 (Use several sheets if necessary)

Date Submitted to PTO: July 24, 2006

ATTY DOCKET NO.
 2006_0979A

SERIAL NO.
 NEW

APPLICANT
 Peter HEROLD et al.

FILING DATE
 July 24, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/G.S./	AA	5,223,615	6/1993	Toyoda et al.			
	AB	5,272,268	12/1993	Toyoda et al.			
	AC	5,194,608	3/1993	Toyoda et al.			
	AD	2004/0044072	3/2004	TenBrink et al.			
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/G.S./	AJ	03/050073	6/2003	WO			
/G.S./	AK	0 468 641	1/1992	Europe			
	AL						
	AM						
	AN						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/G.S./	AO	J.M. Wood et al., "Structure-based design of aliskiren, a novel orally effective renin inhibitor", Biochemical and Biophysical Research Communications, Academic Press Inc., vol. 308, no. 4, pages 698-705, XP004447169, ISSN: 0006-291X, September 5, 2003.
/G.S./	AP	K. Allikmets, "Aliskiren Speedel", Current Opinion in Investigational Drugs, Pharmapress, U.S., vol. 3, no. 10, pages 1479-1482, XP009017210, ISSN: 1472-4472, 2002.
/G.S./	AQ	P. Raddatz et al., "Renin Inhibitors Containing New P1-P1' Dipeptide Mimetics with Heterocycles in P1", Journal of Medicinal Chemistry, American Chemical Society, vol. 35, no. 19, pages 3525-3536, XP002050635, ISSN: 0022-2623, September 18, 1992.

EXAMINER

/Golam Shameem/

DATE CONSIDERED

03/26/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.S./